Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

About the News from Incyte and Vertex

January 28, 2016 0

Incyte: A Good Company Facing Irrelevant Investors’ Reaction Incyte decided to stop an early ongoing trial …

Exelixis Has Good News About CABO

January 28, 2016 0

EXELIXIS Good News about CABO The FDA has determined that Exelixis’ (EXEL) cabozantinib New Drug Application (NDA) …

Halozyme: Reading the News While Keeping Our Focus on the Promises

January 27, 2016 0

Halozyme Therapeutics (HALO) seems to have closed the previously announced $150 million royalty-backed debt transaction with investment …

Theravance Biopharma: Launching Vibativ in Canada for MRSA

January 26, 2016 0

Theravance Biopharma (TBPH) announced the commercial launch of VIBATIV® (telavancin) in Canada. VIBATIV is a once-daily antibiotic …

Revolutionary Approaches Towards Managing Chronic and Deadly Diseases

January 22, 2016 0

The Market is Surely Ignoring the Historical Summit Biotech achievements are standing on Right Now …

OIL: A Blessing or a Curse? It Depends on What Some Want it to Be

January 20, 2016 0

Escaping the slaughter, or taking advantage of it, or accumulating the stocks we love, or turning …

Prohost Letter #390

January 15, 2016 0

Prohost Letter #390 COMPANIES USING CRISPR GENE EDITING TOOLS - The Firms Launched with CRISPR Patents Either …

Of the Biotech Sector Selloff. Spark Presents its Current and Future Programs

January 12, 2016 0

Of the Biotech Sector’s Selloff Testing the lows in biotech firms’ stock prices is nothing but …

The Two Pianists: Breakthrough in the Diagnosis and Treatment of Diseases. See Also: Illumina

January 11, 2016 0

The Evolution of Liquid Biopsy TWO PIANISTS, GUARDANT HEALTH and C4 THERAPEUTICS Biotech firms are bringing …

Steps Forward in the Management of Inflammatory and Autoimmune Diseases

January 8, 2016 0

Improving the management of inflammatory and autoimmune diseases has been a dream that seems to be …

Exelixis Has Good News

January 5, 2016 0

Exelixis Announces Positive Results from Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib …

How Far Can the Market Go in Ignoring Gilead?

January 5, 2016 0

On Oct. 28, 2015, Gilead Sciences (GILD) announced that it has submitted a New Drug Application …

Who Skipped the Bloody Market? Why Gilead Embarked on Galapagos NV Drug Filgotonib?

January 4, 2016 0

The market looks like angry, probably very angry, as stocks are in a severe selloff mood. …

Prohost Letter #389

January 2, 2016 0

Prohost Letter #389 Happy New Year 2016 Wishing You Good Health Peace of Mind Love And …

Array Rallies on Successful NEMO Trial Results of Binetinib on NRAS-Mutant Melanoma

December 16, 2015 0

When you do your due diligence, you do not lose your faith in what you believed …

Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer

December 10, 2015 0

Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, “Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances …

Xoma: Good News for the Firm We Love and Hate But We Never Divorce

December 2, 2015 0

XOMA Announces License Agreement with Novo Nordisk for XMetA Program in Diabetes – Novo Nordisk acquires …

Prohost Letter #388

December 2, 2015 0

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY …

BioMarin: What Happened During the FDA Committee Meeting?

November 25, 2015 0

In our yesterday’s article asking about how the FDA advisory committee has to vote regarding Biomarin …

BioMarin: The DMD Drug and the FDA Committee Options

November 24, 2015 0

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd